Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine

FASEB Journal

Volumn 27, Issue 3, 2013, Pages 1153-1166

  Pusic, Kae ^a   Aguilar, Zoraida ^b,c   McLoughlin, Jaclyn ^a,d   Kobuch, Sophie ^a   Xu, Hong ^b   Tsang, Mazie ^a   Wang, Andrew ^b   Hui, George ^a  

^a UNIVERSITY OF HAWAII   (United States)

^b OCEAN NANOTECH LLC   (United States)

^c Department of Immunochemistry   (United States)

^d California Stem Cell Inc   (United States)

Author keywords

Adjuvant; Inhibitory antibodies; Particle mediated immunizations

Indexed keywords

CARBON TETRACHLORIDE; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; IRON OXIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MALARIA VACCINE; MONTANIDE ISA 51; NANOPARTICLE; RECOMBINANT MEROZOITE SURFACE PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; FREEZE DRYING; IMMUNE RESPONSE; IMMUNIZATION; MACROPHAGE; MALARIA FALCIPARUM; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; AOTIDAE; CYTOKINES; DENDRITIC CELLS; DRUG CARRIERS; FERRIC COMPOUNDS; HUMANS; IMMUNIZATION; MACROPHAGES; MALARIA; MALARIA VACCINES; MEROZOITE SURFACE PROTEIN 1; MICE; NANOPARTICLES; VACCINES, SYNTHETIC;

EID: 84874586492     PISSN: None     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.12-218362     Document Type: Article

References (67)

1. Lambrecht, B. N., Kool, M., Willart, M. A., and Hammad, H. (2009) Mechanism of action of clinically approved adjuvants. Curr. Opin. Immunol. 21, 23-29
2. Mbow, M. L., De Gregorio, E., Valiante, N. M., and Rappuoli, R. (2010) New adjuvants for human vaccines. Curr. Opin. Immunol. 22, 411-416
3. Peek, L. J., Middaugh, C. R., and Berkland, C. (2008) Nanotechnology in vaccine delivery. Adv. Drug Deliv. Rev. 60, 915-928
4. Akagi, T., Wang, X., Uto, T., Baba, M., and Akashi, M. (2007) Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly(amino acid) derivatives. Biomaterials 28, 3427-3436 (Pubitemid 46729729)
5. Lu, J. M., Wang, X., Marin-Muller, C., Wang, H., Lin, P. H., Yao, Q., and Chen, C. (2009) Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev. Mol. Diagn. 9, 325-341
6. Mundargi, R. C., Babu, V. R., Rangaswamy, V., Patel, P., and Aminabhavi, T. M. (2008) Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-coglycolide) and its derivatives. J. Contr. Release 125, 193-209
7. Shive, M. S., and Anderson, J. M. (1997) Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 28, 5-24 (Pubitemid 27497671)
8. Chackerian, B. (2007) Virus-like particles: flexible platforms for vaccine development. Expert Rev. Vaccines 6, 381-390 (Pubitemid 46911601)
9. Ludwig, C., and Wagner, R. (2007) Virus-like particles-universal molecular toolboxes. Curr. Opin. Biotechnol. 18, 537-545
10. Sun, H. X., Xie, Y., and Ye, Y. P. (2009) ISCOMs and ISCOMATRIX. Vaccine 27, 4388-4401
11. Skene, C. D., and Sutton, P. (2006) Saponin-adjuvanted particulate vaccines for clinical use. Methods 40, 53-59 (Pubitemid 44415498)
12. Masotti, A., and Ortaggi, G. (2009) Chitosan micro- and nanospheres: fabrication and applications for drug and DNA delivery. Mini Rev. Med. Chem. 9, 463-469
13. Van der Lubben, I. M., Verhoef, J. C., Borchard, G., and Junginger, H. E. (2001) Chitosan for mucosal vaccination. Adv. Drug Deliv. Rev. 52, 139-144 (Pubitemid 33079169)
14. Illum, L., Jabbal-Gill, I., Hinchcliffe, M., Fisher, A. N., and Davis, S. S. (2001) Chitosan as a novel nasal delivery system for vaccines. Adv. Drug Deliv. Rev. 51, 81-96 (Pubitemid 32763074)
15. Ueno, Y., Futagawa, H., Takagi, Y., Ueno, A., and Mizushima, Y. (2005) Drug-incorporating calcium carbonate nanoparticles for a new delivery system. J. Control. Release 103, 93-98 (Pubitemid 40248564)
16. Szmuness, W., Stevens, C. E., Harley, E. J., Zang, E. A., Oleszko, W. R., William, D. C., Sadovsky, R., Morrison, J. M., and Kellner, A. (1980) Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N. Engl. J. Med. 303, 833-841 (Pubitemid 10014927)
17. Harro, C. D., Pang, Y. Y., Roden, R. B., Hildesheim, A., Wang, Z., Reynolds, M. J., Mast, T. C., Robinson, R., Murphy, B. R., Karron, R. A., Dillner, J., Schiller, J. T., and Lowy, D. R. (2001) Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. 93, 284-292 (Pubitemid 32219815)
18. Kaba, S. A., Brando, C., Guo, Q., Mittelholzer, C., Raman, S., Tropel, D., Aebi, U., Burkhard, P., and Lanar, D. E. (2009) A nonadjuvanted polypeptide nanoparticle vaccine confers longlasting protection against rodent malaria. J. Immunol. 183, 7268-7277
19. Fischer, N. O., Infante, E., Ishikawa, T., Blanchette, C. D., Bourne, N., Hoeprich, P. D., and Mason, P. W. (2010) Conjugation to nickel-chelating nanolipoprotein particles increases the potency and efficacy of subunit vaccines to prevent West Nile encephalitis. Bioconjug. Chem. 21, 1018-1022
20. Hirosue, S., Kourtis, I. C., van der Vlies, A. J., Hubbell, J. A., and Swartz, M. A. (2010) Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation. Vaccine 28, 7897-7906
21. Rudra, J. S., Mishra, S., Chong, A. S., Mitchell, R. A., Nardin, E. H., Nussenzweig, V., and Collier, J. H. (2012) Self-assembled peptide nanofibers raising durable antibody responses against a malaria epitope. Biomaterials 33, 6476-6484
22. Alexis, F., Pridgen, E., Molnar, L. K., and Farokhzad, O. C. (2008) Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5, 505-515
23. Figuerola, A., Di Corato, R., Manna, L., and Pellegrino, T. (2010) From iron oxide nanoparticles towards advanced ironbased inorganic materials designed for biomedical applications. Pharmacol. Res. 62, 126-143
24. Anzai, Y. (2004) Superparamagnetic iron oxide nanoparticles: nodal metastases and beyond. TMRI 15, 103-111 (Pubitemid 38987409)
25. Xu, H., Aguilar, Z. P., Su, H. P., Dixon, J. D., Wei, H., and Wang, A. Y. (2009) Breast cancer cell imaging using semiconductor quantum dots. ECS Transactions 25, 69-77
26. Xu, H., Aguilar, Z. P., and Wang, A. Y. (2010) Quantum dot based sensors for proteins. ECS Transactions 25, 1-8
27. Xu, H., Wei, H., Aguilar, Z. P., Waldron, J. L., and Wang, A. Y. (2009) Application of semiconductor quantum dots for breast cancer cell sensing. Biomedical Engineering and Informatics, BMEI '09. 2nd International Conference on Bioengineering; Communication, Networking & Broadcasting; Computing & Processing (Hardware/ Software). doi: 10.1109/BMEI.2009.5305551
28. Holder, A. A., Blackman, M. J., Burghaus, P. A., Chappel, J. A., Ling, I. T., McCallum-Deighton, N., and Shai, S. (1992) A malaria merozoite surface protein (MSP1)-structure, processing and function. Mem. Inst. Oswaldo Cruz 87(Suppl. 3), 37-42
29. Holder, A. A., and Freeman, R. R. (1984) The three major antigens on the surface of Plasmodium falciparum merozoites are derived from a single high molecular weight precursor. J. Exp. Med. 160, 624-629 (Pubitemid 14052523)
30. Kumar, S., Collins, W., Egan, A., Yadava, A., Garraud, O., Blackman, M. J., Guevara Patino, J. A., Diggs, C., and Kaslow, D. C. (2000) Immunogenicity and efficacy in aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1. Infect. Immun. 68, 2215-2223 (Pubitemid 30164857)
31. Holder, A. A., Guevara Patino, J. A., Uthaipibull, C., Syed, S. E., Ling, I. T., Scott-Finnigan, T., and Blackman, M. J. (1999) Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria. Parassitologia 41, 409-414 (Pubitemid 129640287)
32. Singh, S., Miura, K., Zhou, H., Muratova, O., Keegan, B., Miles, A., Martin, L. B., Saul, A. J., Miller, L. H., and Long, C. A. (2006) Immunity to recombinant Plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect. Immun. 74, 4573-4580 (Pubitemid 44157244)
33. Chang, S. P., Case, S. E., Gosnell, W. L., Hashimoto, A., Kramer, K. J., Tam, L. Q., Hashiro, C. Q., Nikaido, C. M., Gibson, H. L., Lee-Ng, C. T., Barr, P. J., Yokota, B. T., and Hut, G. S. (1996) A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Infect. Immun. 64, 253-261 (Pubitemid 26009363)
34. Stowers, A. W., Cioce, V., Shimp, R. L., Lawson, M., Hui, G., Muratova, O., Kaslow, D. C., Robinson, R., Long, C. A., and Miller, L. H. (2001) Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial. Infect. Immun. 69, 1536-1546 (Pubitemid 32187606)
35. Egan, A. F., Burghaus, P., Druilhe, P., Holder, A. A., and Riley, E. M. (1999) Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite Immunol. 21, 133-139 (Pubitemid 29118866)
36. Al Yaman, F., Genton, B., Kramer, K. J., Chang, S. P., Hui, G. S., Baisor, M., and Alpers, M. P. (1996) Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean children from malaria morbidity. Amer. J. Trop. Med. Hygiene 54, 443-448 (Pubitemid 26162236)
37. John, C. C., O'Donnell, R. A., Sumba, P. O., Moormann, A. M., Koning-Ward, T. F., King, C. L., Kazura, J. W., and Crabb, B. S. (2004) Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. J. Immunol. 173, 666-672 (Pubitemid 38797397)
38. O'Donnell, R. A., Koning-Ward, T. F., Burt, R. A., Bockarie, M., Reeder, J. C., Cowman, A. F., and Crabb, B. S. (2001) Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. J. Exp. Med. 193, 1403-1412 (Pubitemid 32565969)
39. Perraut, R., Marrama, L., Diouf, B., Sokhna, C., Tall, A., Nabeth, P., Trape, J. F., Longacre, S., and Mercereau-Puijalon, O. (2005) Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village. J. Infect. Disease 191, 264-271 (Pubitemid 40096385)
40. Kirkpatrick, R. B., Shatzman, A., Fernandez, J., and Hoeffler, J. (1999) Drosophila S2 system for heterologous gene expression. In Gene Expression Systems: Using Nature for the Art of Expression (Fernandez, J. M, and Hoeffler, J. P., eds) pp. 289-330, Academic Press, New York
41. Chang, S. P., Gibson, H. L., Lee-Ng, C. T., Barr, P. J., and Hui, G. S. (1992) A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth. J. Immunol. 149, 548-555
42. Pusic, K. M., Hashimoto, C. N., Lehrer, A., Aniya, C., Clements, D. E., and Hui, G. S. (2011) T cell epitope regions of the P. falciparum MSP1-33 critically influence immune responses and in vitro efficacy of MSP1-42 vaccines. PLoS One 6, e24782
43. Pusic, K., Xu, H., Stridiron, A., Aguilar, Z., Wang, A., and Hui, G. (2011) Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodies. Vaccine 29, 8898-8908
44. Hui, G. S., Hashimoto, A. C., Nikaido, C. M., Choi, J., and Chang, S. P. (1994) Induction of antibodies to the Plasmodium falciparum merozoite surface protein-1 (MSP1) by cross-priming with heterologous MSP1s. J. Immunol. 153, 1195-1201 (Pubitemid 24228511)
45. Chang, S. P., Hui, G. S., Kato, A., and Siddiqui, W. A. (1989) Generalized immunological recognition of the major merozoite surface antigen (gp195) of Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A. 86, 6343-6347 (Pubitemid 19210648)
46. Hui, G. S., Gosnell, W. L., Case, S. E., Hashiro, C., Nikaido, C., Hashimoto, A., and Kaslow, D. C. (1994) Immunogenicity of the C-terminal 19-kDa fragment of the Plasmodium falciparum merozoite surface protein 1 (MSP1), YMSP1(19) expressed in S. cerevisiae. J. Immunol. 153, 2544-2553
47. Hui, G., and Hashimoto, C. (2007) The requirement of CD80, CD86, and ICAM-1 on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum bloodstage vaccine. Vaccine 25, 8549-8556 (Pubitemid 350192044)
48. Hui, G., Choe, D., and Hashimoto, C. (2008) Biological activities of anti-merozoite surface protein-1 antibodies induced by adjuvant-assisted immunizations in mice with different immune gene knockouts. Clin. Vaccine Immunol. 15, 1145-1150
49. Hui, G. S., and Siddiqui, W. A. (1987) Serum from Pf195 protected Aotus monkeys inhibit Plasmodium falciparum growth in vitro. Exp. Parasitol. 64, 519-522 (Pubitemid 18012349)
50. Lambros, C., and Vanderberg, J. P. (1979) Synchronization of Plasmodium falciparum erythrocytic stages in culture. J. Parasitol. 65, 418-420 (Pubitemid 10222999)
51. Leung, W. H., Meng, Z. Q., Hui, G., and Ho, W. K. (2004) Expression of an immunologically reactive merozoite surface protein (MSP-1(42)) in E. coli. Biochim. Biophys. Acta 1675, 62-70 (Pubitemid 39463255)
52. Pang, A. L., Hashimoto, C. N., Tam, L. Q., Meng, Z. Q., Hui, G. S., and Ho, W. K. (2002) In vivo expression and immunological studies of the 42-kilodalton carboxyl-terminal processing fragment of Plasmodium falciparum merozoite surface protein 1 in the baculovirus-silkworm system. Infect. Immun. 70, 2772-2779 (Pubitemid 34564131)
53. Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., and Steinman, R. M. (1992) Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colonystimulating factor. J. Exp. Med. 176, 1693-1702
54. Zhang, X., Goncalves, R., and Mosser, D. M. (2008) The isolation and characterization of murine macrophages. Curr. Protoc. Immunol. Chapter 14, Unit 14 11
55. Szymczak, W. A., and Deepe, G. S., Jr. (2010) Antigen-presenting dendritic cells rescue CD4-depleted CCR2-/- mice from lethal Histoplasma capsulatum infection. Infect. Immun. 78, 2125-2137
56. Livak, K. J., and Schmittgen, T. D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402-408 (Pubitemid 34164012)
57. Pfaffl, M. W. (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45
58. Hui, G., and Hashimoto, C. (2007) Plasmodium falciparum anti- MSP1-19 antibodies induced by MSP1-42 and MSP1-19 based vaccines differed in specificity and parasite growth inhibition in terms of recognition of conserved versus variant epitopes. Vaccine 25, 948-956 (Pubitemid 44856116)
59. Shahiwala, A., Vyas, T. K., and Amiji, M. M. (2007) Nanocarriers for systemic and mucosal vaccine delivery. Recent Pat. Drug Deliv. Form. 1, 1-9
60. Hui, G. S., Chang, S. P., Gibson, H., Hashimoto, A., Hashiro, C., Barr, P. J., and Kotani, S. (1991) Influence of adjuvants on the antibody specificity to the Plasmodium falciparum major merozoite surface protein, gp195. J. Immunol. 147, 3935-3941
61. Hui, G. S. (1994) Liposomes, muramyl dipeptide derivatives, and nontoxic lipid A derivatives as adjuvants for human malaria vaccines. Am. J. Trop. Med. Hyg. 50, 41-51 (Pubitemid 24158403)
62. Hui, G. S., and Chang, S. P. (1992) Plasmodium falciparum: induction of biologically active antibodies to gp195 is dependent on the choice of adjuvants. Exp. Parasitol. 75, 155-157
63. Ferrari, M. (2005) Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 5, 161-171 (Pubitemid 40314948)
64. Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., and Langer, R. (2007) Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751-760 (Pubitemid 350223348)
65. Gao, X., Cui, Y., Levenson, R. M., Chung, L. W., and Nie, S. (2004) In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol. 22, 969-976 (Pubitemid 39014473)
66. Barton, G. M., and Kagan, J. C. (2009) A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat. Rev. Immunol. 9, 535-542
67. Pasare, C., and Medzhitov, R. (2005) Toll-like receptors: linking innate and adaptive immunity. Adv. Exp. Med. Biol. 560, 11-18